NasalOxy®: A NEXT-GENERATION LOW-FLOW OXYGEN THERAPY INTERFACE FOR ENHANCED OXYGENATION AND PATIENT COMFORT
Low-flow oxygen therapy remains a cornerstone in the management of acute and chronic respiratory
, including COPD, pneumonia, and chronic respiratory insufficiency, where effective and consistent oxygen delivery is essential. However, conventional oxygen delivery systems, particularly nasal cannulas, are frequently associated with limitations in oxygenation efficiency, mucosal irritation, and reduced patient adherence [1,2].
CNSAC NasalOxy® is a patented nasal/oral oxygen delivery interface designed to address these challenges through a prong-free design and a novel oxygen distribution mechanism. This white paper evaluates the clinical rationale, technological innovation, and therapeutic relevance of NasalOxy®.
Oxygen therapy is a fundamental treatment for patients with hypoxemia and respiratory failure and is strongly recommended in international clinical guidelines [1]. Its effectiveness depends not only on the oxygen flow rate but also on the efficiency of the oxygen delivery device and patient compliance.
Conventional nasal cannulas remain widely used due to their simplicity; however, oxygen delivery efficiency
may be affected by variations in breathing patterns and the dilution of oxygen with ambient air [2]. Prolonged
use is also associated with dryness and irritation of the nasal mucosa, a risk of nosebleeds, and reduced patient tolerance over time.
This document examines how CNSAC NasalOxy®, a patented nasal/oral oxygen delivery interface, overcomes the limitations of conventional systems by generating a localized stream of oxygen-enriched air in the breathing zone. It facilitates more efficient oxygen uptake through both the nasal and oral passages while enhancing patient comfort.
Figure 1: NasalOxy® low-flow oxygen interface with a prongless oxygen delivery design
The NasalOxy® interface is designed to deliver low-flow oxygen through a diffuse, non-intranasal oxygen delivery system positioned below the nostrils. Unlike conventional nasal cannulas, the design does not require intranasal prongs, thereby minimizing direct contact with the nasal mucosa. The interface is intended to support both nasal and oral breathing while improving comfort during prolonged oxygen therapy and daily activities.
The clinical limitations of traditional oxygen delivery systems extend beyond patient comfort and directly affect treatment stability by
. Oxygen delivery via nasal prongs is inherently restricted to the nasal-
-airway, reducing its effectiveness in patients who rely partially or predominantly on oral breathing.
Furthermore, during routine activities such as speaking or eating, the effectiveness of oxygen delivery via
standard nasal cannulas may be reduced due to increased mouth breathing and variable inspiratory-
-patterns.
- Route limitation: oxygen delivery remains ineffective in patients who primarily breathe through their mouths
- Intermittent delivery: oxygen intake is interrupted during daily activities, reducing the consistency of therapy
- Interface-related discomfort: The use of standard nasal cannulas may cause dryness, irritation, and inflammation of the nasal passages, occasionally leading to nosebleeds and localized pain.
NasalOxy® introduces a fundamentally different approach based on oxygen distribution within the breathing zone rather than direct intranasal insufflation. The device is positioned externally—
—between the nose and mouth and utilizes a patented oxygen distributor with a swirler-based mechanism [6]. This system creates a stable, oxygen-enriched airflow that can be inhaled simultaneously through both nasal and oral air
.
Figure 2: Illustration of the NasalOxy® oxygen distribution concept
NasalOxy® delivers a gentle, diffuse flow of oxygen around the nose and mouth to support low-flow oxygen therapy without the use of intranasal prongs.
- Prong-free interface positioned on the upper lip
- Swirler mechanism for controlled oxygen dispersion
- Formation of a localized “oxygen cloud”
- Multi-axis joint for anatomical adaptability
The device generates a localized oxygen-rich airflow, increasing the partial pressure of oxygen in the breathing zone and improving diffusion efficiency. Unlike traditional cannulas, this method ensures more consistent delivery. This design reflects a shift from anatomy-dependent delivery toward breathing-centered oxygen therapy, building on earlier concepts of simultaneous mouth and nose breathing [5].
- Oxygen cloud formation, increasing local oxygen availability
- Dual airway delivery, allowing for both nasal and oral breathing
- Reduced mucosal contact, minimizing irritation and dryness
Figure 3: Effect of NasalOxy® on arterial blood gas pO₂ during low-flow oxygen therapy
Comparative evaluations showed higher mean arterial pO₂ values with NasalOxy® compared with conventional nasal cannulas at oxygen flow rates of 2 LPM and 5 LPM. The bars represent the mean ± SD after 20 minutes of oxygen administration.
In a controlled clinical evaluation in patients with respiratory insufficiency, NasalOxy® was associated with significant improvements in arterial oxygenation parameters at standard low-flow settings. Increases in PaO₂ of approximately 28% at 2 L/min and 71% at 5 L/min were observed, alongside significant improvements in SpO₂ (p < 0.01) [7 and Fig. 3].
Figure 4. Comparison of NasalOxy® and conventional nasal cannulas during low-flow oxygen therapy
NasalOxy® is a prongless oxygen delivery interface designed to facilitate oxygen administration during both nasal and oral breathing while minimizing direct contact with the nasal mucosa. Compared with conventional nasal cannulas, NasalOxy® may improve patient comfort, reduce mucosal irritation, and ensure more stable oxygen delivery during low-flow oxygen therapy.
By supporting more stable oxygen delivery during routine activities such as speaking and eating, NasalOxy® may help reduce fluctuations in oxygenation and improve overall therapy consistency.
Real-world user feedback indicates that NasalOxy® improves usability and comfort compared to conventional nasal cannulas. Reported benefits include reduced nasal irritation and dryness, improved sleep quality, and more stable oxygen levels during daily activities.
Figure 5. Patient-centered use of NasalOxy® during long-term low-flow oxygen therapy
Illustration of a patient using the NasalOxy® prong-free oxygen interface. Real-world user feedback indicates improved comfort and tolerance during prolonged oxygen therapy, including reduced nasal dryness and irritation commonly associated with conventional intranasal cannulas. Users also frequently report improved comfort during sleep and daily activities. The interface is designed to support both nasal and oral breathing while minimizing direct contact with the mucous membranes.
NasalOxy® may be considered for patients requiring low-flow oxygen therapy (1–6 L/min) who experience discomfort or intolerance with conventional nasal cannulas, exhibit mixed nasal/oral breathing patterns, or seek improved comfort during long-term oxygen therapy.
Final patient selection and clinical decision-making remain the responsibility of the treating healthcare professional.
NasalOxy® can be positioned as a comfortable alternative within long-term oxygen therapy programs and a practical solution for both clinical and home-care settings. The device integrates seamlessly without altering the oxygen source, flow settings, or established monitoring protocols. Modern oxygen therapy guidelines emphasize individualized treatment, continuous monitoring, and the appropriate selection of delivery systems [3,4].
- Minimal training required thanks to its intuitive, prong-free design
- No complicated setup or calibration
- Supports immediate patient acceptance and autonomy
NasalOxy® is designed to support more comfortable and adaptable low-flow oxygen therapy by combining clinically effective oxygen delivery with a prong-free, patient-centered interface.
By addressing the practical limitations of conventional nasal cannulas, NasalOxy® aims to improve long-term usability, comfort, and patient compliance in both clinical and home-care settings.
For clinical inquiries, distribution opportunities, or product information, please contact CNSAC.
- Conventional nasal cannulas are associated with oxygen dilution, mucosal irritation, and limited effectiveness during oral breathing
- NasalOxy® creates a localized stream of oxygen-enriched air in the breathing zone, supporting both nasal and oral inhalation
- Clinical evaluation showed significant improvements in PaO₂ (28% at 2 L/min, 71% at 5 L/min) and SpO₂
- The prong-free design significantly improves patient comfort and tolerance
- NasalOxy® offers a patient-centered, next-generation solution for low-flow oxygen therapy
1. Koczulla AR, Schneeberger T, Jarosch I, Kenn K, Gloeckl R. Long-term oxygen therapy. Dtsch Arztebl Int.
2018;115(51-52):871-877. doi:10.3238/arztebl.2018.08712. Sharma S, Danckers M, Sanghavi DK, Chakraborty RK. High-flow nasal cannula. StatPearls [Internet]. Treasure
Island (FL): StatPearls Publishing; 2026. PMID:302523273. O’Driscoll BR, Howard LS, Earis J, Mak V; British Thoracic Society Emergency Oxygen Guideline Group; BTS
Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and
emergency settings. Thorax. 2017;72(Suppl 1):ii1-ii90. doi:10.1136/thoraxjnl-2016-2097294. Barnett A, Beasley R, Buchan C, Chien J, Farah CS, King G, et al. Position statement by the Thoracic Society of Australia and New Zealand’
s on acute oxygen use in adults: “Swimming between the flags”. Respirology. 2022;27:262–
276. doi:10.1111/resp.142185. Köhler D, Knoch M, Sommerfeld C, Müller H. A new oxygen applicator for simultaneous mouth- and nose-
-breathing. Chest. 1993;103(4):1157-1160. doi:10.1378/chest.103.4.11576. Köhler D, Löwenstein R. Oxygen distributor for use in oxygen inhalation therapy. European Patent EP2578262B1.
European Patent Office; 2017.7. Kianian A, Ghafoori T, Abu Hassan O. A new low-flow oxygen cannula provides advanced oxygen delivery via a h
, allowing simultaneous oral and nasal breathing. CNSAC Internal Study. Published 2024. Accessed May 14, 2026.
https://www.cnsac-medshop.com/en/blogs/unkategorisiert/low-flow-oxygen-cannulanasaloxy